구.추천논문
- 조회2,352
전북대학교 의과대학
Abstract
Seoung Ju Park,2,*,† Kyung Sun Lee,2,*,† So Ri Kim,*,† Kyung Hoon Min,*,† Yeong Hun Choe,*,† Hee Moon,*,† Han Jung Chae,†,‡ Wan Hee Yoo,*,† and Yong Chul Lee3,*, †
*Department of Internal Medicine, Research Center for Pulmonary Disorders, and Department of Pharmacology, Chonbuk National University Medical School, Jeonju, South Korea
Peroxisome proliferator-activated receptor γ (PPARγ) plays a critical role in the control of airway inflammation. Recently, IL-17 has been found to be implicated in many immune and inflammatory responses, including airway inflammation. However, no data are available concerning the effect of PPARγ on IL-17 production in airway inflammatory diseases. In this study, we used a mouse model of asthma to evaluate the effect of two PPAR agonists, rosiglitazone or pioglitazone, on IL-17 expression in allergic airway disease. After OVA inhalation, mice developed the typical pathophysiological features of asthma, and the expression of IL-17 protein and mRNA in the lungs was increased. Administration of rosiglitazone or pioglitazone reduced the pathophysiological features of asthma and decreased the increased IL-17 protein and mRNA expression after OVA inhalation. In addition, the attenuating effect of PPARγ agonist on allergic airway inflammation and bronchial hyperresponsiveness is abrogated by coadministration of rIL-17. This study also showed that the inhibition of IL-17 activity with anti-IL-17 Ab remarkably reduced the increased numbers of inflammatory cells of the airways, airway hyperresponsiveness, and the increased levels of IL-4, IL-5, and IL-13 in bronchoalveolar lavage fluid and OVA-specific IgE in serum. In addition, we found that administration of rosiglitazone or pioglitazone decreased the increased NF-κB activity and that a NF-κB inhibitor, BAY 11-7085, substantially reduced the increased IL-17 protein levels in the lung tissues after OVA inhalation. These findings suggest that the therapeutic effect of PPAR in asthma is partly mediated by regulation of IL-17 expression via NF-κB pathway.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This study was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea (A084144).
2 These authors contributed equally to this work.
3 Address correspondence and reprint requests to Dr. Yong Chul Lee, Department of Internal Medicine, Chonbuk National University Medical School, San 2-20 Geumam-dong, Deokjin-gu, Jeonju, Jeonbuk 561-180, South Korea.
4 Abbreviations used in this paper: BALF, bronchoalveolar lavage fluid; BAL, bronchoalveolar lavage; PAS, periodic acid-Schiff; PPAR, peroxisome proliferator-activated receptor; Rrs, respiratory system resistance.
논문정보
- Research article
- 2009년 07월 (BRIC 등록일 )
- 국내 연구진
- 구・추천논문
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
